1
|
Abbad-Jaime de Aragón C, Berna-Rico E, Jaén P, Blauvelt A, González-Cantero Á. Rapid resolution of guttate psoriasis without recurrence for one year following two doses of guselkumab. Int J Dermatol 2024; 63:534-535. [PMID: 38305493 DOI: 10.1111/ijd.17055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 01/16/2024] [Indexed: 02/03/2024]
Affiliation(s)
- Carlota Abbad-Jaime de Aragón
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
- Psoriasis and Inflammatory Skin Diseases Unit, Grupo Pedro Jaén, Madrid, Spain
| | - Emilio Berna-Rico
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - Pedro Jaén
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
- Psoriasis and Inflammatory Skin Diseases Unit, Grupo Pedro Jaén, Madrid, Spain
| | | | - Álvaro González-Cantero
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
- Psoriasis and Inflammatory Skin Diseases Unit, Grupo Pedro Jaén, Madrid, Spain
- Facultad de Medicina, Universidad Francisco de Vitoria, Ctra, Pozuelo de Alarcón, Spain
| |
Collapse
|
2
|
Martorell A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R, Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferran-Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Suarez-Perez JA, González-Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, Del Alcázar-Viladomiu E, García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-Velasco M, Vilarrasa E, Velasco-Pastor M, De la Cueva P, Carrascosa JM, Magdaleno-Tapial J. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study. Actas Dermosifiliogr 2024:S0001-7310(24)00187-X. [PMID: 38452889 DOI: 10.1016/j.ad.2024.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Accepted: 02/24/2024] [Indexed: 03/09/2024] Open
Abstract
BACKGROUND AND OBJECTIVE Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. OBJECTIVE To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice. METHODS This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52. RESULTS A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7±14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30kg/m2). The mean baseline PASI score was 11.4±7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30kg/m2 on weeks 4 (P=.04), 16 (P=.001), and 52 (P=.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P=.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P=.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment. CONCLUSIONS Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.
Collapse
Affiliation(s)
- A Martorell
- Department of Dermatology, Hospital de Manises, Valencia, Spain.
| | - S Santos-Alarcón
- Department of Dermatology, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain
| | - A Sahuquillo-Torralba
- Department of Dermatology, Hospital General Universitario Dr. Balmis-ISABIAL-UMH, Alicante, Spain
| | - R Rivera-Díaz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - I Belinchón-Romero
- Department of Dermatology, Hospital General Universitario Dr. Balmis-ISABIAL-UMH, Alicante, Spain
| | - D Ruiz-Genao
- Department of Dermatology, Hospital Universitario de Alcorcón, Madrid, Spain
| | - A Romero-Maté
- Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - R Ruiz-Villaverde
- Department of Dermatology, Hospital Universitario PTS, Granada, Spain
| | - M Ferran-Farrés
- Department of Dermatology, Hospital del Mar, Barcelona, Spain
| | | | - M Almenara-Blasco
- Department of Dermatology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - J A Suarez-Perez
- Department of Dermatology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
| | - Á González-Cantero
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain; Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
| | | | | | | | - J García-Latasa
- Department of Dermatology, Hospital Royo Villanova, Zaragoza, Spain
| | | | - M Ara-Martín
- Department of Dermatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - A Mateu-Puchades
- Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain
| | - M Llamas-Velasco
- Department of Dermatology, Hospital de la Princesa, Madrid, Spain
| | - E Vilarrasa
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - P De la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, UAB, IGTP, Badalona, Barcelona, Spain
| | - J Magdaleno-Tapial
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
| |
Collapse
|
3
|
Abbad-Jaime de Aragón C, Berna-Rico E, Goas A, Pérez-Bootello J, Ballester-Martinez MA, Jaén P, Blauvelt A, González-Cantero Á. Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis. Clin Exp Dermatol 2024; 49:272-273. [PMID: 37878574 DOI: 10.1093/ced/llad361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 11/07/2023] [Indexed: 10/27/2023]
Abstract
This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of < 1.
Collapse
Affiliation(s)
| | - Emilio Berna-Rico
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS . Madrid, Spain
| | - Almudena Goas
- Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
| | - Javier Pérez-Bootello
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS . Madrid, Spain
| | | | - Pedro Jaén
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS . Madrid, Spain
| | | | - Álvaro González-Cantero
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS . Madrid, Spain
- Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
| |
Collapse
|
4
|
Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML, Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén Olasolo P. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study. Actas Dermosifiliogr 2024; 115:10-20. [PMID: 37442420 DOI: 10.1016/j.ad.2023.06.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 06/21/2023] [Accepted: 06/28/2023] [Indexed: 07/15/2023] Open
Abstract
BACKGROUND AND OBJECTIVE A significant proportion of women of childbearing age have psoriasis. The aim of this study was to examine family planning concerns in this population. MATERIAL AND METHODS Observational, descriptive, cross-sectional, multicenter study conducted between March 2020 and October 2021. We collected sociodemographic data and analyzed responses to a family planning questionnaire administered to women aged 18 to 45 years with plaque psoriasis who were candidates for systemic treatment. RESULTS We studied 153 patients (mean [SD] age, 35.4 [8.0] years; mean disease duration, 16.7 years) being treated at 11 Spanish hospitals. Overall, 38.4% of women were considered to have moderate to severe psoriasis by their physicians; perceived severity ratings were significantly higher among women. Psoriasis affected the women's desire to become pregnant or led to their delaying pregnancy in 1 in 3 respondents. They were concerned that their condition might worsen if they had to discontinue or switch treatment or that the treatment might harm the baby. Approximately half of the women had not received family planning counseling from their physicians, and this was more likely to be the case among never-pregnant women. Women on biologic therapy (58.7%) had better psoriasis control and a better quality of life than women on other treatments. Their sexual health was also less affected. CONCLUSIONS Women with psoriasis have numerous family planning concerns, which in some cases can lead them to delay pregnancy or affect their desire to become pregnant. Dermatologists need to receive better training regarding family planning in women with psoriasis so that they can provide their patients with more and better information.
Collapse
Affiliation(s)
- N Jiménez Gómez
- Hospital Universitario Ramón y Cajal, Madrid, España; Grupo de Dermatología Pedro Jaén, Madrid, España.
| | - Á González-Cantero
- Hospital Universitario Ramón y Cajal, Madrid, España; Grupo de Dermatología Pedro Jaén, Madrid, España; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, España
| | - R Ruiz-Villaverde
- Hospital Universitario San Cecilio Granada, Instituto Biosanitario de Granada (Ibs), Granada, España
| | | | | | - R Rivera Díaz
- Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, España
| | | | | | | | | | - G Pitarch Bort
- Hospital General Universitario de Castellón, Castellón, España
| | | | - P Jaén Olasolo
- Hospital Universitario Ramón y Cajal, Madrid, España; Grupo de Dermatología Pedro Jaén, Madrid, España
| |
Collapse
|
5
|
Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML, Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén Olasolo P. [Translated article] Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study. Actas Dermo-Sifiliográficas 2024; 115:T10-T20. [PMID: 37923069 DOI: 10.1016/j.ad.2023.10.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 06/28/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND AND OBJECTIVE A significant proportion of women of childbearing age have psoriasis. The aim of this study was to examine family planning concerns in this population. MATERIAL AND METHODS Observational, descriptive, cross-sectional, multicenter study conducted between March 2020 and October 2021. We collected sociodemographic data and analyzed responses to a family planning questionnaire administered to women aged 18 to 45 years with plaque psoriasis who were candidates for systemic treatment. RESULTS We studied 153 patients (mean [SD] age, 35.4 [8.0] years; mean disease duration, 16.7 years) being treated at 11 Spanish hospitals. Overall, 38.4% of women were considered to have moderate to severe psoriasis by their physicians; perceived severity ratings were significantly higher among women. Psoriasis affected the women's desire to become pregnant or led to their delaying pregnancy in 1 in 3 respondents. They were concerned that their condition might worsen if they had to discontinue or switch treatment or that the treatment might harm the baby. Approximately half of the women had not received family planning counseling from their physicians, and this was more likely to be the case among never-pregnant women. Women on biologic therapy (58.7%) had better psoriasis control and a better quality of life than women on other treatments. Their sexual health was also less affected. CONCLUSIONS Women with psoriasis have numerous family planning concerns, which in some cases can lead them to delay pregnancy or affect their desire to become pregnant. Dermatologists need to receive better training regarding family planning in women with psoriasis so that they can provide their patients with more and better information.
Collapse
Affiliation(s)
- N Jiménez Gómez
- Hospital Universitario Ramón y Cajal, Madrid, Spain; Grupo de Dermatología Pedro Jaén, Madrid, Spain.
| | - Á González-Cantero
- Hospital Universitario Ramón y Cajal, Madrid, Spain; Grupo de Dermatología Pedro Jaén, Madrid, Spain; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain
| | - R Ruiz-Villaverde
- Hospital Universitario San Cecilio Granada, Instituto Biosanitario de Granada (Ibs), Granada, Spain
| | | | | | - R Rivera Díaz
- Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain
| | | | | | | | | | - G Pitarch Bort
- Hospital General Universitario de Castellón, Castellón, Spain
| | | | - P Jaén Olasolo
- Hospital Universitario Ramón y Cajal, Madrid, Spain; Grupo de Dermatología Pedro Jaén, Madrid, Spain
| |
Collapse
|
6
|
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol 2023; 37:2517-2525. [PMID: 37625815 DOI: 10.1111/jdv.19468] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 07/05/2023] [Indexed: 08/27/2023]
Abstract
BACKGROUND Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the effectiveness and safety of tildrakizumab is limited. OBJECTIVES To assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate-to-severe plaque psoriasis in routine clinical practice. METHODS Retrospective, observational, multicentre study including adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab under real-life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22. RESULTS A total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study. CONCLUSION Tildrakizumab was effective and safe in a large cohort of patients with moderate-to-severe plaque psoriasis treated in a routine clinical setting.
Collapse
Affiliation(s)
| | | | | | | | - Anna López-Ferrer
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jorge Santos-Juanes
- Department of Dermatology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Mercedes Hospital-Gil
- Department of Dermatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
| | | | | | | | - Marta Ferran
- Department of Dermatology, Hospital del Mar, Barcelona, Spain
| | - Elena Del Alcázar
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | | | | | | | | | - Diana Ruíz-Genao
- Department of Dermatology, Hospital Universitario Fundación Alcorcon, Madrid, Spain
| | - Noemí Eiris-Salvado
- Department of Dermatology, Complejo Asistencial Universitario de León, León, Spain
| | | | - Raquel Rivera-Diaz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Pablo de la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Esteban Daudén
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain
| | | | - Mar Llamas-Velasco
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain
| |
Collapse
|
7
|
Abbad-Jaime de Aragón C, Berna-Rico E, Ballester-Martinez MA, Jaén P, Solís J, Barderas MG, Fernández-Friera L, N Mehta N, Gelfand JM, González-Cantero Á. Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study. BMJ Open 2023; 13:e072455. [PMID: 37751953 PMCID: PMC10533786 DOI: 10.1136/bmjopen-2023-072455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 08/16/2023] [Indexed: 09/30/2023] Open
Abstract
INTRODUCTION Life expectancy of patients with psoriasis is reduced by 4-5 years due to cardiovascular disease with an increased risk of myocardial infarction at an earlier age compared with the general population. This increased risk is independent of traditional cardiovascular risk factors and higher in moderate-to-severe forms of psoriasis. Inflammation may play a key role in the development of atherosclerosis in these patients. METHODS AND ANALYSIS A prospective cohort study, Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP), was initiated in January 2020 to investigate the presence and progression of subclinical atherosclerosis in patients with psoriasis. 120 patients aged 30-65 years and eligible for biological treatment have been recruited at Hospital Ramón y Cajal in Madrid, Spain. Patients undergo a baseline visit, and 1-year follow-up visit after starting biological therapy. Each visit includes: assessment of cardiovascular risk factors, screening for subclinical atherosclerosis by two-dimensional/three-dimensional ultrasound of carotid and femoral arteries, cardiac CT of coronary arteries and blood sampling. All baseline visits were completed by December 2022, and the remaining follow-up visits will be concluded by the end of 2023. The EDSAP study aims to identify new molecular and imaging markers associated with the presence of atherosclerosis and its progression in a chronic inflammatory state such as psoriasis. This has the potential to: (1) help improve primary cardiovascular prevention strategies in these patients; (2) understand the effect of biological drugs on the cardiovascular system; and (3) serve as a model for understanding atherosclerosis in other chronic inflammatory diseases. ETHICS AND DISSEMINATION The study protocol has been approved by the Institutional Review Board of the Hospital Ramón y Cajal in Madrid. We will present our findings at national and international congresses, and peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT05858099.
Collapse
Affiliation(s)
| | | | | | - Pedro Jaén
- Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain
| | - Jorge Solís
- Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
- Cardiology, Atria Clinic, Madrid, Spain
| | - María G Barderas
- Vascular Physiopathology, Hospital Nacional de Parapléjicos, IDISCAM, Toledo, Spain
| | - Leticia Fernández-Friera
- Cardiology, Atria Clinic, Madrid, Spain
- Centro Integral de Enfermedades Cardiovasculares HM CIEC, HM Hospitales, Madrid, Spain
| | - Nehal N Mehta
- Cardiology, George Washington Medical Center, Washington, DC, USA
| | - Joel M Gelfand
- Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Álvaro González-Cantero
- Dermatology, Hospital Universitario Ramon y Cajal, Madrid, Spain
- Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcon, Comunidad de Madrid, Spain
| |
Collapse
|
8
|
Alonso-Naranjo L, Berna-Rico E, Blanco Abbad-Jaime de Aragón C, Castañeda-Vozmediano R, Prieto-López L, Sánchez-Moya AI, Pérez-Hortet C, González-Cantero Á. Spanish Version of Teenagers’ Quality of Life (T-QoL) for Adolescents with Skin Diseases: Translation, Cultural Adaptation and Validation. Actas Dermosifiliogr 2023; 114:T299-T307. [PMID: 36868511 DOI: 10.1016/j.ad.2023.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 01/15/2023] [Indexed: 03/05/2023] Open
Abstract
BACKGROUND Teenagers' Quality of Life (T-QoL) is an age-specific measure to assess QoL of teenagers suffering from different skin diseases. A validated Spanish language version is lacking. We present the translation, cultural adaptation and validation of the T-QoL into Spanish. METHODS A prospective study with 133 patients (between 12-19 years old), attended at the dermatology department of Toledo University Hospital, Spain, (September 2019-May 2020), was carried out for the validation study. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were used for the translation and cultural adaptation. We evaluated the convergent validity with the Dermatology Life Quality Index (DLQI), the Children's Dermatology Life Quality Index (CDLQI) and with a Global Question (GQ) on self-assessed disease severity. We also analysed internal consistency and reliability of the T-QoL tool and confirmed its structure with a factor analysis. RESULTS Global T-QoL scores significantly correlated with the DLQI and the CDLQI (r=0.75) and with the GQ (r=0.63). The Confirmatory Factor Analysis showed optimal fit for the bi-factor model and an adequate fit for the correlated three-factor model. Reliability indicators were high (Cronbach's α=0.89; Guttman's Lambda 6 index=0.91; Omega ω=0.91) and test-retest showed a high stability (ICC=0.85). The results were consistent with those found by the authors of the original test. CONCLUSION Our Spanish version of the T-QoL tool is valid and reliable to assess QoL of Spanish-speaking adolescents with skin diseases.
Collapse
Affiliation(s)
- L Alonso-Naranjo
- Departamento de Dermatología, Hospital Universitario de Toledo, Toledo, España
| | - E Berna-Rico
- Departamento de Dermatología, Hospital Universitario Ramón y Cajal, Madrid, España
| | | | | | - L Prieto-López
- Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, España
| | - A I Sánchez-Moya
- Departamento de Dermatología, Hospital Universitario de Toledo, Toledo, España
| | - C Pérez-Hortet
- Departamento de Dermatología, Hospital Universitario de Toledo, Toledo, España
| | - Á González-Cantero
- Departamento de Dermatología, Hospital Universitario Ramón y Cajal, Madrid, España; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, España.
| |
Collapse
|
9
|
Alonso-Naranjo L, Berna-Rico E, Blanco Abbad-Jaime de Aragón C, Castañeda-Vozmediano R, Prieto-López L, Sánchez-Moya AI, Pérez-Hortet C, González-Cantero Á. Spanish Version of Teenagers' Quality of Life (T-QoL) for Adolescents with Skin Diseases: Translation, Cultural Adaptation and Validation. Actas Dermosifiliogr 2023; 114:299-307. [PMID: 36690147 DOI: 10.1016/j.ad.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/11/2023] [Accepted: 01/15/2023] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Teenagers' Quality of Life (T-QoL) is an age-specific measure to assess QoL of teenagers suffering from different skin diseases. A validated Spanish language version is lacking. We present the translation, cultural adaptation and validation of the T-QoL into Spanish. METHODS A prospective study with 133 patients (between 12 and 19 years old), attended at the dermatology department of Toledo University Hospital, Spain (September 2019-May 2020), was carried out for the validation study. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were used for the translation and cultural adaptation. We evaluated the convergent validity with the Dermatology Life Quality Index (DLQI), the Children's Dermatology Life Quality Index (CDLQI) and with a Global Question (GQ) on self-assessed disease severity. We also analysed internal consistency and reliability of the T-QoL tool and confirmed its structure with a factor analysis. RESULTS Global T-QoL scores significantly correlated with the DLQI and the CDLQI (r=0.75) and with the GQ (r=0.63). The confirmatory factor analysis showed optimal fit for the bi-factor model and an adequate fit for the correlated three-factor model. Reliability indicators were high (Cronbach's α=0.89; Guttman's Lambda 6 index=0.91; Omega ω=0.91) and test-retest showed a high stability (ICC=0.85). The results were consistent with those found by the authors of the original test. CONCLUSION Our Spanish version of the T-QoL tool is valid and reliable to assess QoL of Spanish-speaking adolescents with skin diseases.
Collapse
Affiliation(s)
- L Alonso-Naranjo
- Department of Dermatology, Hospital Universitario de Toledo, Toledo, Spain
| | - E Berna-Rico
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | | | | | - L Prieto-López
- Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
| | - A I Sánchez-Moya
- Department of Dermatology, Hospital Universitario de Toledo, Toledo, Spain
| | - C Pérez-Hortet
- Department of Dermatology, Hospital Universitario de Toledo, Toledo, Spain
| | - Á González-Cantero
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain; Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
| |
Collapse
|
10
|
Vidal S, Puig L, Carrascosa-Carrillo JM, González-Cantero Á, Ruiz-Carrascosa JC, Velasco-Pastor AM. Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740. Int J Mol Sci 2022; 23:ijms23052649. [PMID: 35270045 PMCID: PMC8910060 DOI: 10.3390/ijms23052649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 12/16/2021] [Indexed: 11/16/2022] Open
Abstract
In the original publication [...].
Collapse
Affiliation(s)
- Silvia Vidal
- Institute of Research, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain;
- Correspondence: ; Tel.: +34-93-553-7544
| | - Lluís Puig
- Institute of Research, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain;
| | | | - Álvaro González-Cantero
- Department of Dermatology, Hospital Universitario Ramón y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain;
- Facultad de Medicina, Universidad Francisco de Vitoria, Ctra. Pozuelo-Majadahonda KM 1.800, 28223 Pozuelo de Alarcón, Spain
| | | | | |
Collapse
|
11
|
Laborde CM, Larzabal L, González-Cantero Á, Castro-Santos P, Díaz-Peña R. Advances of Genomic Medicine in Psoriatic Arthritis. J Pers Med 2022; 12:jpm12010035. [PMID: 35055350 PMCID: PMC8780979 DOI: 10.3390/jpm12010035] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 12/16/2021] [Accepted: 12/28/2021] [Indexed: 12/13/2022] Open
Abstract
Psoriatic arthritis (PsA) is a common type of inflammatory arthritis found in up to 40% of patients with psoriasis. Although early diagnosis is important for reducing the risk of irreversible structural damage, there are no adequate screening tools for this purpose, and there are no clear markers of predisposition to the disease. Much evidence indicates that PsA disorder is complex and heterogeneous, where genetic and environmental factors converge to trigger inflammatory events and the development of the disease. Nevertheless, the etiologic events that underlie PsA are complex and not completely understood. In this review, we describe the existing data in PsA in order to highlight the need for further research in this disease to progress in the knowledge of its pathobiology and to obtain early diagnosis tools for these patients.
Collapse
Affiliation(s)
| | | | - Álvaro González-Cantero
- Department of Dermatology, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain;
- Faculty of Medicine, Universidad Francisco de Vitoria, Ctra. Pozuelo-Majadahonda, 28223 Pozuelo de Alarcón, 28034 Madrid, Spain
| | - Patricia Castro-Santos
- Immunology, Centro de Investigaciones Biomédicas (CINBIO), Universidad de Vigo, 36310 Vigo, Spain;
| | - Roberto Díaz-Peña
- Faculty of Health Sciences, Universidad Autónoma de Chile, Talca 3460000, Chile
- Correspondence: or ; Tel.: +34-981-955-073
| |
Collapse
|
12
|
Belinchón Romero I, Dauden E, Ferrándiz Foraster C, González-Cantero Á, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med 2021; 53:1727-1736. [PMID: 34601988 PMCID: PMC8491706 DOI: 10.1080/07853890.2021.1986637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 09/22/2021] [Indexed: 11/07/2022] Open
Abstract
OBJECTIVE To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis. METHODS Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi procedure were carried out. A steering committee from the Spanish Group of Psoriasis was established who based on the reviews generated a set of related statements. Subsequently, a group of 40 experts tested their agreement with the statements, through 3 Delphi rounds. RESULTS We found a great variability in clinical guidelines regarding to the definition of treatment goal and the response. In general, treatment failure was considered if a PASI50 is not achieved. The panel of experts agreed on (1) clearly differentiate between ideal and a realistic goals when establishing the therapeutic goal in moderate to severe psoriasis; (2) treatment goals should be in general established regardless of the type of drug for psoriasis; (3) treatment failure if PASI75 response is not reached; (4) an absolute PASI is in general preferred to the rate of PASI improvement from baseline; (5) disease characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals. CONCLUSIONS A clear treatment decision making framework is vital to improve management of psoriasis.KEY MESSAGESPsoriasis characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals.Different disease indexes could be used to assess treatment response but absolute PASI is preferredIn general psoriasis treatment failure should be considered if PASI75 response is not reached.
Collapse
Affiliation(s)
- Isabel Belinchón Romero
- Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain
| | - Esteban Dauden
- Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain
| | - Carlos Ferrándiz Foraster
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, e IGTP, Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Jose Manuel Carrascosa Carrillo
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, e IGTP, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
13
|
Belinchón Romero I, Dauden E, Ferrándiz Foraster C, González-Cantero Á, Carrascosa Carrillo JM. PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. J DERMATOL TREAT 2021; 33:1661-1669. [PMID: 33615959 DOI: 10.1080/09546634.2021.1890683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Response to treatments in psoriasis can be assessed using the PASI response 50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the patient's basal lesions. Therefore, PASI 100 score has been increasingly used in the context of research, but its role in daily practice is currently controversial. OBJECTIVE (1) To analyze PASI 100 response rates to pharmacological treatments; (2) To examine clinical practice guidelines (CPGs) recommendations/comments on PASI 100. METHODS We conducted a systematic literature review (SLR). Selection criteria concerned patients with psoriasis, reporting PASI 100. RESULTS Overall, 65 studies were included. Patients on methotrexate achieved at 16 weeks a PASI 100 of 7.3%. For TNF inhibitors rates were: 3.7-11.1% at 12 weeks, 13.7-20% at 16 weeks, 10.7-24% at 24 weeks and 21.8-34.8% at 1 year. IL-17 inhibitors achieved 23.3-44% at 12 weeks, 44.3-57.2% at 16 weeks, 39.7-67.5% at 24 weeks and 41.4-67.5% at 1 year. And the reported by IL-12/23 inhibitors were 12%/23.8% at 12 weeks, 32.7%/50% at 16 weeks, 44% at 24 weeks and 41.8%/56.3% at 1 year. PASI 100 response is scarcely commented in the CPGs. CONCLUSIONS PASI 100 response rate is an endpoint fundamentally restricted to research.
Collapse
Affiliation(s)
- Isabel Belinchón Romero
- Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain
| | - Esteban Dauden
- Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain
| | - Carlos Ferrándiz Foraster
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol and IGTP. Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Jose Manuel Carrascosa Carrillo
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol and IGTP. Universitat Autònoma de Barcelona, Barcelona, Spain
| | | |
Collapse
|
14
|
Alonso-Naranjo L, González-Cantero Á. Pustular psoriasis of pregnancy managed with labor induction. Eur J Obstet Gynecol Reprod Biol 2021; 259:224-225. [PMID: 33637333 DOI: 10.1016/j.ejogrb.2021.01.043] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 01/21/2021] [Indexed: 10/22/2022]
|
15
|
Llamas-Velasco M, Baniandrés O, Rivera R, Reymundo Jimenez A, Hospital M, García Zamora E, González-Cantero Á, Andrés Lencina JJ, Daudén E, de la Cueva P. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg. Dermatol Ther 2020; 33:e13678. [PMID: 32447810 DOI: 10.1111/dth.13678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 05/04/2020] [Accepted: 05/21/2020] [Indexed: 11/27/2022]
Abstract
A change of pricing policy in Spain have made both doses of ustekinumab (UST), 45 and 90 mg, recently available at the same price. Our primary objective was to evaluate effectiveness of UST 90 mg at 52 and 104 weeks in psoriasis patients in clinical practice; secondary objectives were to study the reasons for using this dose and to delineate its efficacy in patients previously treated with anti-IL17 drugs. 91.8% of the 141 patients treated with UST 90 started with 45 mg and later increased their dose. Clinicians changed dose due to weight over 100 kg in 20.6% of the cases and all the other dose changes were off-label to improve partial cutaneous or articular response or due to a previous failure of anti-IL17 therapy. After 12 months of UST 90 treatment, absolute PASI was lower than 3 in 87.5% of patients and lower than 1 in 72.2%. Efficacy data were even better for patients with body mass index (BMI) <25. UST 90 can be effective in patients with previous use of anti-IL17 drugs. It appears to be an alternative treatment option not only for high BMI patients, but also to increase the cutaneous or articular efficacy of the drug in patients with normal BMI.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Álvaro González-Cantero
- Hospital Universitario Ramón y Cajal. Previously at Complejo Hospitalario de Toledo, Madrid, Spain
| | | | | | | |
Collapse
|
16
|
González-Cantero Á, Moreno-Torres B, Gargallo-Quintero A. Calcifilaxia en paciente trasplantado renal. Rev Clin Esp 2019; 219:458-459. [DOI: 10.1016/j.rce.2018.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2018] [Revised: 07/29/2018] [Accepted: 08/08/2018] [Indexed: 10/28/2022]
|
17
|
González-Cantero Á, Moreno-Torres B, Gargallo-Quintero A. Calciphylaxis in a kidney transplant patient. Rev Clin Esp 2019. [DOI: 10.1016/j.rceng.2018.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
González-Cantero Á, Sánchez-Moya A, Pérez-Hortet C. Effect of Biologic Therapy on Cardiovascular Risk in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2019. [DOI: 10.1016/j.adengl.2018.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
González-Cantero Á, Sánchez-Moya A, Pérez-Hortet C. FR- Tratamientos biológicos y su efecto en el riesgo cardiovascular de los pacientes con psoriasis. Actas Dermo-Sifiliográficas 2019; 110:685-686. [DOI: 10.1016/j.ad.2018.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2018] [Revised: 08/02/2018] [Accepted: 08/03/2018] [Indexed: 10/27/2022] Open
|
20
|
Molina-Figuera E, González-Cantero Á, Martínez-Lorenzo E, Sánchez-Moya AI, García-Olmedo O, Gómez-Dorado B, Schoendorff-Ortega C. Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast. J Cutan Med Surg 2019; 22:104-105. [PMID: 29309244 DOI: 10.1177/1203475417733464] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | | | | | | | | | - Blas Gómez-Dorado
- 1 Servicio de Dermatología, Complejo Hospitalario de Toledo, Toledo, Spain
| | | |
Collapse
|
21
|
González-Cantero Á, Gatica-Ortega ME, Pastor-Nieto MA, Martínez-Lorenzo ER, Gómez-Dorado BA, Mollejo-Villanueva M, Tapia-de-Pedro G, Martínez-Camacho M, Pérez-Hortet C. Acute generalized exanthematous pustulosis (AGEP)-like contact dermatitis resulting from topical therapy in a polysensitized patient. Contact Dermatitis 2018; 80:329-333. [PMID: 30578535 DOI: 10.1111/cod.13204] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 12/10/2018] [Accepted: 12/16/2018] [Indexed: 11/28/2022]
Affiliation(s)
| | | | - María-Antonia Pastor-Nieto
- Dermatology Department, University Hospital of Guadalajara, Guadalajara, Spain.,Department of Medicine, Alcalá de Henares University, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
22
|
González-Cantero Á, Sánchez-Moya AI, Pérez-Hortet C, Martinez-Lorenzo E, Gómez-Dorado B, Molina-Figuera E, García-Olmedo O, Schoendorff-Ortega C, Sherry DD. Complex regional pain syndrome of the face in a child. Int J Dermatol 2018; 57:1502-1503. [DOI: 10.1111/ijd.14045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 04/09/2018] [Accepted: 04/23/2018] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | | | - Blas Gómez-Dorado
- Department of Dermatology; Complejo Hospitalario de Toledo; Toledo Spain
| | | | | | | | - David D. Sherry
- Division of Rheumatology; Department of Pediatrics; The Children's Hospital of Philadelphia; Philadelphia PA USA
| |
Collapse
|
23
|
González-Cantero Á, González-Cantero J, Sánchez-Moya A, Pérez-Hortet C, Schoendorff-Ortega C. Comment on “Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population With Psoriasis”. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2018.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
24
|
González-Cantero Á, González-Cantero J, Sánchez-Moya A, Pérez-Hortet C, Schoendorff-Ortega C. Réplica a «Factores de riesgo cardiovascular y grosor de la íntima media carotídea en una población colombiana con psoriasis». Actas Dermo-Sifiliográficas 2018; 109:848-849. [DOI: 10.1016/j.ad.2018.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 02/11/2018] [Indexed: 11/26/2022] Open
|
25
|
González-Cantero Á, Sánchez-Moya AI, Martínez-Lorenzo E, Pérez-Hortet C, Schoendorff-Ortega C. Subcutaneous Sarcoidosis With Dactylitis. J Cutan Med Surg 2018; 22:506. [PMID: 30168385 DOI: 10.1177/1203475418758991] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
González-Cantero Á, González-Cantero J, Sánchez-Moya AI, Pérez-Hortet C, Schoendorff-Ortega C. Psoriasis and subclinical atherosclerosis in a Chinese population. Australas J Dermatol 2018. [PMID: 29516475 DOI: 10.1111/ajd.12804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
González-Cantero Á, Honorato-Guerra S, Sánchez-Moya AI, Arias-Santiago S, Moreno-Torres B, Martinez-Lorenzo E, Mollejo M, Schoendorff-Ortega C. Comment on: "A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients". Am J Clin Dermatol 2017; 18:709-711. [PMID: 28653140 DOI: 10.1007/s40257-017-0309-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | | | | | - Salvador Arias-Santiago
- Unidad de Gestión Clínica de Dermatología, Complejo Hospitalario Universidad de Granada, Granada, Spain
| | | | | | - Manuela Mollejo
- Servicio de Anatomía Patológica, Complejo Hospitalario de Toledo, Toledo, Spain
| | | |
Collapse
|
28
|
González-Cantero Á, Sánchez-Moya AI, Pérez-Hortet C, Martínez-Lorenzo E, Gómez-Dorado B, Schoendorff-Ortega C. "Nails Only" Phenotype and Partial Dominance of p.Glu170Lys Mutation in a Family with Epidermolysis Bullosa Simplex. Pediatr Dermatol 2017; 34:e205-e206. [PMID: 28425111 DOI: 10.1111/pde.13146] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Epidermolysis bullosa (EB) is a heterogeneous group of rare, chronic, inherited skin disorders characterized by marked mechanical fragility of epithelial tissues, with blistering and erosions after minor trauma. We present the first report of a nails-only phenotype in two patients with epidermolysis bullosa simplex (EBS) and a heterozygous pGlu170Lys mutation and the second reported case of EBS associated with a homozygous p.Glu170Lys mutation in the KRT5 gene. Our findings may be relevant for genetic counseling and for understanding the inheritance pattern of EBS.
Collapse
Affiliation(s)
| | | | | | | | - Blas Gómez-Dorado
- Department of Dermatology, Complejo Hospitalario de Toledo, Toledo, Spain
| | | |
Collapse
|